Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) has a Wall Street consensus price target of $7.84, based on estimates from 11 covering analysts. With the stock currently trading at $6.75, this represents a potential upside of +16.1%. The company has a market capitalization of $328M.
Analyst price targets range from a low of $4.35 to a high of $12.00, representing a 98% spread in expectations. The median target of $7.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, DNA trades at a trailing P/E of -1.2x. Analysts expect EPS to grow +35.6% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how DNA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonGinkgo Bioworks Holdings, Inc. (DNA) has a consensus 12-month price target of $7.84, implying 16.1% upside from $6.75. The 11 analysts covering DNA see moderate appreciation potential.
DNA has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $7.84 implies 16.1% upside from current levels.
DNA's current price is $6.75 with a consensus target of $7.84 (16.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for DNA, while the most conservative target is $4.35. The consensus of $7.84 represents the median expectation. These targets typically reflect 12-month expectations.
DNA is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 2 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DNA stock forecast based on 11 Wall Street analysts shows a consensus price target of $7.84, with estimates ranging from $4.35 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are optimistic on DNA, with a "Buy" consensus rating and $7.84 price target (16.1% upside). 5 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DNA analyst price targets range from $4.35 to $12, a 98% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7.84 consensus represents the middle ground.